AR107083A1 - ANTIBODIES DIRECTED TO CD32B AND METHODS OF USE OF THE SAME - Google Patents

ANTIBODIES DIRECTED TO CD32B AND METHODS OF USE OF THE SAME

Info

Publication number
AR107083A1
AR107083A1 ARP160103892A ARP160103892A AR107083A1 AR 107083 A1 AR107083 A1 AR 107083A1 AR P160103892 A ARP160103892 A AR P160103892A AR P160103892 A ARP160103892 A AR P160103892A AR 107083 A1 AR107083 A1 AR 107083A1
Authority
AR
Argentina
Prior art keywords
seq
amino acid
acid sequence
chain variable
variable region
Prior art date
Application number
ARP160103892A
Other languages
Spanish (es)
Inventor
Xu Fangmin
Wilson Nicholas
John Meyer Matthew
Lu Haihui
Isnardi Isabelle
Adkins Huet Heather
Harris Alan
Ewert Stefan
Calzascia Yhomas
Balke Nicole
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR107083A1 publication Critical patent/AR107083A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

La presente solicitud se refiere a anticuerpos aislados y fragmentos de unión a antígeno de los mismos que se unen selectivamente a CD32b humano. Reivindicación 1: Un anticuerpo aislado o fragmento de unión a antígeno del mismo, que comprende: (a) una región variable de cadena pesada CDR1 que comprende una secuencia de aminoácidos seleccionada de cualquiera de las SEQ ID Nº 1, 4, 7, 53, 56, 59, 105, 108, 111, 157, 160, 163, 209, 212, 215, 261, 264, 267, 313, 316, 319, 365, 368, 371, 417, 420, 423, 469, 472, 475, 521, 524, 527, 547, 550, 553, 573, 576, 579, 625, 628, y 631; (b) una CDR2 de la región variable de cadena pesada que comprende una secuencia de aminoácidos seleccionada entre cualquiera de las SEC ID Nº 2, 5, 8, 54, 57, 60, 106, 109, 112, 158, 161, 164, 210, 213, 216, 262, 265, 268, 314, 317, 320, 366, 369, 372, 418, 421; 424, 470, 473, 476, 522, 525, 528, 548, 551, 554, 574, 577, 580, 626, 629, y 632; (c) una CDR3 de la región variable de cadena pesada que comprende una secuencia de aminoácidos seleccionada entre cualquiera de las SEC ID Nº 3, 6, 9, 55, 58, 61, 107, 110, 113, 159, 162, 165, 211, 214, 217, 263, 266, 269, 315, 318, 321, 367, 370, 373, 419, 422, 425, 471, 474, 477, 523, 526, 529, 549, 552, 555, 575, 578, 581, 627, 630 y 633; (d) una CDR1 de la región variable de cadena ligera que comprende una secuencia de aminoácidos seleccionada entre cualquiera de las SEC ID Nº 14, 17, 20, 66, 69, 72, 118, 121, 124, 170, 173, 176, 222, 225, 228, 274, 277, 280, 326, 329, 332, 378, 381, 384, 430, 433, 436, 482, 485, 488, 534, 537, 540, 560, 563, 566, 586, 589, 592, 638, 641, 644; (e) una CDR2 de la región variable de cadena ligera que comprende una secuencia de aminoácidos seleccionada entre cualquiera de las SEC ID Nº 15, 18, 21, 67, 70, 73, 119, 122, 125, 171, 174, 177, 223, 226, 229, 275, 278, 281, 327, 330, 333, 379, 382, 385, 431, 434, 437, 483, 486, 489, 535, 538, 541, 561, 564, 567, 587, 590, 593, 639, 642 y 645; y (f) una CDR3 de la región variable de cadena ligera que comprende una secuencia de aminoácidos seleccionada entre cualquiera de las SEC ID Nº 16, 19, 22, 68, 71, 74, 120, 123, 126, 172, 175, 178, 224, 227, 230, 276, 279, 282, 328, 331, 334, 380, 383, 386, 432, 435, 438, 484, 487, 490, 536, 539, 542, 562, 565, 568, 588, 591, 594, 640, 643 y 646; en el que el anticuerpo se une selectivamente a CD32b humana.The present application relates to isolated antibodies and antigen binding fragments thereof that selectively bind human CD32b. Claim 1: An isolated antibody or antigen-binding fragment thereof, comprising: (a) a CDR1 heavy chain variable region comprising an amino acid sequence selected from any of SEQ ID Nos. 1, 4, 7, 53, 56, 59, 105, 108, 111, 157, 160, 163, 209, 212, 215, 261, 264, 267, 313, 316, 319, 365, 368, 371, 417, 420, 423, 469, 472, 475, 521, 524, 527, 547, 550, 553, 573, 576, 579, 625, 628, and 631; (b) a CDR2 of the heavy chain variable region comprising an amino acid sequence selected from any of SEQ ID NO: 2, 5, 8, 54, 57, 60, 106, 109, 112, 158, 161, 164, 210, 213, 216, 262, 265, 268, 314, 317, 320, 366, 369, 372, 418, 421; 424, 470, 473, 476, 522, 525, 528, 548, 551, 554, 574, 577, 580, 626, 629, and 632; (c) a CDR3 of the heavy chain variable region comprising an amino acid sequence selected from any of SEQ ID NO: 3, 6, 9, 55, 58, 61, 107, 110, 113, 159, 162, 165, 211, 214, 217, 263, 266, 269, 315, 318, 321, 367, 370, 373, 419, 422, 425, 471, 474, 477, 523, 526, 529, 549, 552, 555, 575, 578, 581, 627, 630 and 633; (d) a CDR1 of the light chain variable region comprising an amino acid sequence selected from any of SEQ ID NOS 14, 17, 20, 66, 69, 72, 118, 121, 124, 170, 173, 176, 222, 225, 228, 274, 277, 280, 326, 329, 332, 378, 381, 384, 430, 433, 436, 482, 485, 488, 534, 537, 540, 560, 563, 566, 586, 589, 592, 638, 641, 644; (e) a CDR2 of the light chain variable region comprising an amino acid sequence selected from any of SEQ ID NO: 15, 18, 21, 67, 70, 73, 119, 122, 125, 171, 174, 177, 223, 226, 229, 275, 278, 281, 327, 330, 333, 379, 382, 385, 431, 434, 437, 483, 486, 489, 535, 538, 541, 561, 564, 567, 587, 590, 593, 639, 642 and 645; and (f) a CDR3 of the light chain variable region comprising an amino acid sequence selected from any of SEQ ID NOS 16, 19, 22, 68, 71, 74, 120, 123, 126, 172, 175, 178 , 224, 227, 230, 276, 279, 282, 328, 331, 334, 380, 383, 386, 432, 435, 438, 484, 487, 490, 536, 539, 542, 562, 565, 568, 588 , 591, 594, 640, 643 and 646; wherein the antibody selectively binds to human CD32b.

ARP160103892A 2015-12-18 2016-12-16 ANTIBODIES DIRECTED TO CD32B AND METHODS OF USE OF THE SAME AR107083A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562269444P 2015-12-18 2015-12-18

Publications (1)

Publication Number Publication Date
AR107083A1 true AR107083A1 (en) 2018-03-21

Family

ID=61768601

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103892A AR107083A1 (en) 2015-12-18 2016-12-16 ANTIBODIES DIRECTED TO CD32B AND METHODS OF USE OF THE SAME

Country Status (1)

Country Link
AR (1) AR107083A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110428870A (en) * 2019-08-08 2019-11-08 苏州泓迅生物科技股份有限公司 A kind of method and its application of prediction heavy chain of antibody light chain pairing probability

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110428870A (en) * 2019-08-08 2019-11-08 苏州泓迅生物科技股份有限公司 A kind of method and its application of prediction heavy chain of antibody light chain pairing probability
CN110428870B (en) * 2019-08-08 2023-03-21 苏州泓迅生物科技股份有限公司 Method for predicting antibody heavy chain and light chain pairing probability and application thereof

Similar Documents

Publication Publication Date Title
CL2019001926A1 (en) Anti-tigit antibodies and antigen-binding fragments; pharmaceutical composition comprising them; polynenucleotide encoding said antibody; vector comprising them, host cell; method of producing said antibody or antigen-binding fragment thereof; and use in the treatment of cancer. (Divisional Application 310-2017).
PE20190737A1 (en) ANTI-CD27 ANTIBODIES
CO2018013500A2 (en) Anti-pd-l1 antibodies and uses thereof
PE20191208A1 (en) ANTI-CD73 ANTIBODIES AND USES OF THEM
CL2020003096A1 (en) Entpd2 Antibodies, Combination Therapies, and Methods of Using Antibodies and Combination Therapies
PE20171180A1 (en) ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE
EA201490053A1 (en) ANTIBODIES THAT ARE BIND OX40 AND THEIR APPLICATION
AR106991A1 (en) NEUTRALIZING ANTIBODIES OF THE HUMAN IMMUNODEFICIENCY VIRUS
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
PE20240111A1 (en) BINDING MOLECULES TO PD-1 AND METHODS OF USE THEREOF
AR106184A1 (en) PD-1 BINDING PROTEINS AND THEIR METHODS OF USE
AR096617A1 (en) ANTI-TWEAKR ANTIBODIES AND THEIR USES
AR105267A1 (en) TAU JOINT ANTIBODIES
PE20180499A1 (en) UNION TO TAU ANTIBODIES
CO6430469A2 (en) HUMANIZED ANTIBODIES THAT JOIN CD19 AND ITS USES
ES2776179T3 (en) Antibodies directed against surface determinants of S. aureus
PE20131403A1 (en) ANTI-OX40 ANTIBODIES AND METHODS OF USING THEM
PE20141908A1 (en) CD47 ANTIBODIES AND METHODS OF USE THEM
PE20131209A1 (en) ANTI-FAP ANTIBODIES
CO2017004753A2 (en) Antibodies that bind to ccr6
UY37030A (en) ANTIBODIES DIRECTED TO CD32B AND METHODS OF USE OF THE SAME
AR109683A1 (en) ANTIBODIES AGAINST FACTOR XI AND ITS USES
ECSP18084153A (en) Humanized anti-BASIGIN antibodies and their use
NZ728981A (en) Anti-ceramide antibodies
PE20190633A1 (en) ANTI-GM-CSF ANTIBODIES AND USES OF THE SAME

Legal Events

Date Code Title Description
FB Suspension of granting procedure